AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 52 min read$RXRX

Khan Najat sold $84K of RXRX

Khan Najat (CEO and President) sold 23,588 shares of RECURSION PHARMACEUTICALS, INC. (RXRX) at $3.58 on 2026-06-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Khan Najat
Published Jun 5, 2026, 9:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 5, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RXRX
Neutral
medium confidence
Mentioned
$RXRX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RXRXNeutralLow
01

Why it matters

The disclosed sale can influence short-term sentiment, but 10b5-1 pre-arrangement typically lowers the likelihood of it signaling new negative information.

02

Market read

A same-day insider selling print for RXRX, partially mitigated by the stated 10b5-1 plan.

03

What to watch

Consider whether other insiders also sold around the same window and whether there are concurrent clinical/regulatory updates not mentioned here.

Relevance 6/10Novelty 6/10Timing: Filed same day as the sale (2026-06-05)

Background

The article is an SEC Form 4 insider transaction disclosure for Recursion Pharmaceuticals’ CEO/President.

Company-level read

Ticker impact

$RXRXNeutralMedium confidence
Context

Recursion Pharmaceuticals CEO/President Khan Najat sold 23,588 shares in an open-market transaction disclosed via SEC Form 4.

Expected impact

Likely limited immediate price impact; watch for follow-on insider activity or concurrent fundamental catalysts.

Evidence & confidence

This is an ownership-change disclosure with transaction details, but it is explicitly under a pre-arranged 10b5-1 plan, which typically dampens signal strength versus discretionary sales.

Market effects

Sector

Adds marginal sentiment noise for biotech/clinical-stage names where insider selling can be interpreted as risk appetite.

Regional

None specific beyond US small/mid-cap biotech tape.

Global

Limited; this is company-specific insider activity.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish fundamentals.

Key entities

  • company
    Recursion Pharmaceuticals, Inc.

    Issuer of the insider transaction; CEO/President sold shares via open-market sale under a 10b5-1 plan.

  • person
    Khan Najat

    CEO and President; reported the sale of 23,588 shares at $3.5806/share.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RXRX insider trading history →

Related articles

OCT 19
$RXRXHighAI 8/10

RXRX Stock Pops As Sanofi Deal And ARK Buying Fuel AI-Drug Hype

Recursion Pharmaceuticals (RXRX) stock rose 4.26% on optimism over AI-driven drug advances. The company reported positive Phase 1b/2 trial results for REC-4881 and early Phase 1 data for REC-1245. Sanofi optioned a candidate, triggering a $10M milestone. RXRX raised $200M, extending its cash runway. The stock has high volatility, trading at a 43x P/S ratio with negative margins.

timothysykes.com3 min
OCT 19
$RXRXHighAI 8/10

RXRX Stock Pops As Sanofi Deal, ARK Buying Fuel AI Biotech Story

Recursion Pharmaceuticals Inc. (RXRX) stock rose 3.85% on AI-driven drug discovery progress and institutional buying. The company reported positive Phase 1b/2 data for REC-4881 and REC-1245, and Sanofi exercised an option on an inflammatory candidate, triggering a $10M milestone. RXRX raised $200M in a follow-on offering, and ARK Investment Management has been accumulating shares. The company has no near-term profits but has a strong cash position and strategic partnerships.

timothysykes.com3 min
OCT 19
$RXRXHighAI 8/10

RXRX Stock Pops As Sanofi Deal, ARK Buying Ignite Momentum

Recursion Pharmaceuticals (RXRX) stock rose 3.85% on news of a Sanofi partnership and ARK Investment's purchases. The company reported positive clinical data for REC-4881 and REC-1245, and raised $200M in equity. RXRX has a strong cash position and a runway into 2029, but remains unprofitable with negative margins.

stockstotrade.com3 min
OCT 16
$RXRXHighAI 9/10

Key facts: RXRX REC-4881 strong efficacy, clean safety; Runway into 2029

Recursion (RXRX) reported positive results from its Phase 1b/2 trial of REC-4881, showing an 87% mean reduction in GI polyp burden and a 92% reduction in upper GI. The drug demonstrated a favorable safety profile, with no treatment-related adverse events above Grade 3. The company plans a registrational trial in H2 2027, pending FDA discussions. Recursion had $561M in cash as of Sept 30, 2026, and expects $200M from a recent offering, extending its runway into 2029.

tradingview.com1 min
OCT 15
$RXRXMed

Recursion (RXRX) Enters New Growth Phase as Sanofi Kicks Off Drug Collab, Shares Soar

Recursion Pharmaceuticals (RXRX) shares surged 17.9% after Sanofi initiated development of drug molecules, triggering a $10M milestone payment, totaling $144M received. RXRX may earn over $300M more in milestones and royalties if approved. The collaboration, started in 2022, focuses on AI-enabled small molecule therapies in immunology and oncology. Hedge fund holdings in RXRX increased 16% QoQ to $287.9M, despite a drop in the number of funds invested.

insidermonkey.com2 min